89bio, INC Form 4 insider transactions

Quoc Le-Nguyen, Chief Technical Operations Officer and Head of Quality at 89bio, Inc., disposed of 5,352 shares of common stock on September 9, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Chief Medical Officer of 89bio, Inc., Harry H. Mansbach, reports the disposition of 1,046 shares of common stock to cover tax obligations related to vesting restricted stock units.

Rohan Palekar, CEO of 89bio, Inc., reports the disposition of 4,601 shares of common stock to cover tax obligations related to vesting restricted stock units.

Ryan Martins, CFO of 89bio, Inc., reports the disposal of 777 common stock shares to cover tax obligations related to vesting restricted stock units.

Quoc Le-Nguyen, Chief Technical Operations Officer and Head of Quality at 89bio, Inc., reports the disposal of 1,046 shares of common stock to cover tax obligations related to vesting restricted stock units.

Director Charles McWherter acquired options to purchase 67,700 shares of 89bio, Inc. common stock on August 5, 2024.

Francis Sarena, Chief Operating Officer of 89bio, Inc., acquired stock options and restricted stock units on August 5, 2024.

Director Martin Babler acquired stock options for 67,700 shares of 89bio, Inc. common stock on May 2, 2024.

RA Capital Management and related entities report the acquisition of 1,408,450 shares of 89bio, Inc. at a price of $5.325 per share, along with warrants to purchase additional shares.

89bio CEO Rohan Palekar exercised stock options and sold a portion of the acquired shares on April 1, 2024, under a pre-arranged trading plan.

RA Capital Management and related entities acquired 1,350,000 shares of 89bio, Inc. at $15.35 per share in an at-the-market offering.

Rohan Palekar, CEO of 89bio, Inc., sold 4,477 shares of common stock at $10.76 per share on February 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.